Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.390
-0.060 (-4.14%)
At close: Jul 24, 2025, 4:00 PM
1.440
+0.050 (3.60%)
Pre-market: Jul 25, 2025, 4:54 AM EDT

Company Description

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform.

The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer.

The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program.

Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Acrivon Therapeutics, Inc.
Acrivon Therapeutics logo
CountryUnited States
Founded2018
IPO DateNov 15, 2022
IndustryBiotechnology
SectorHealthcare
Employees78
CEOPeter Blume-Jensen

Contact Details

Address:
480 Arsenal Way, Suite 100
Watertown, Massachusetts 02472
United States
Phone617 207 8979
Websiteacrivon.com

Stock Details

Ticker SymbolACRV
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$12.50
CIK Code0001781174
CUSIP Number004890109
ISIN NumberUS0048901096
Employer ID82-5125532
SIC Code2834

Key Executives

NamePosition
Dr. Peter Blume-Jensen M.D., Ph.D.Co-Founder, Chairman of the Board, Chief Executive Officer, President and Acting Chief Scientific Officer
Kristina Masson M.B.A., Ph.D.Co-Founder, Executive Vice President of Business Operations, Site Head, Treasurer and Director
Dr. Eric J. Devroe Ph.D.Chief Operating Officer
Dr. Adam D. Levy M.B.A., Ph.D.Chief Financial Officer and Principal Financial Officer
Katharine Peterson CPAVice President of Finance and Accounting
Mary-Alice Miller J.D.Chief Legal Officer and Corporate Secretary
Dr. Erick Gamelin M.D., Ph.D.Chief Development Officer
Dr. Jesper V. Olsen Ph.D.Academic Co-Founder, Head of Phosphoproteomics and Member of Scientific Advisory Board
Joon Jung Ph.D.Vice President and Head of Data Science
Dr. Thomas P. Nifong M.D.Head of Clinical CDx Operations

Latest SEC Filings

DateTypeTitle
Jun 13, 20258-KCurrent Report
Jun 4, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13G/AFiling
May 14, 2025S-8Securities to be offered to employees in employee benefit plans
May 14, 202510-QQuarterly Report
May 14, 20258-KCurrent Report
May 1, 2025SCHEDULE 13G/AFiling
Apr 25, 2025ARSFiling
Apr 25, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2025DEF 14AOther definitive proxy statements